[{"Assets_0_Q3_USD":266890000.0,"EarningsPerShareBasic_1_Q3_USD":1.03,"EarningsPerShareBasic_3_Q3_USD":2.82,"EarningsPerShareDiluted_1_Q3_USD":0.98,"EarningsPerShareDiluted_3_Q3_USD":2.68,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":32998000.0,"NetIncomeLoss_1_Q3_USD":15431000.0,"NetIncomeLoss_3_Q3_USD":42858000.0,"StockholdersEquity_0_Q3_USD":171077000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":15047917.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":15174426.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171108"}]